# G-CSF in the Treatment of Toxic Epidermal Necrolysis

> **NCT02739295** · PHASE4 · COMPLETED · sponsor: **University of Liege** · enrollment: 10 (actual)

## Conditions studied

- Stevens - Johnson Syndrome

## Interventions

- **DRUG:** recombinant granulocyte - colony stimulating factor
- **DRUG:** NaCl 0.9%

## Key facts

- **NCT ID:** NCT02739295
- **Lead sponsor:** University of Liege
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07
- **Primary completion:** 2023-03-07
- **Final completion:** 2023-03-07
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2025-12-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739295, "G-CSF in the Treatment of Toxic Epidermal Necrolysis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02739295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*